WuXi Biologics (Cayman) Inc.

Equities

2269

KYG970081173

Biotechnology & Medical Research

Delayed Hong Kong S.E. Other stock markets 02:08:55 2024-07-18 am EDT			5-day change	1st Jan Change
11.24 ^HKD	-0.35%		+1.26%	-61.96%

Jun. 27	Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14	MT
Jun. 19	Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment	MT

Oxford BioTherapeutics Ltd Designates Second Bispecific Antibody Program Leveraging Wuxi Biologics’ Wuxibody® Platform

January 19, 2021 at 08:00 am EST

WuXi Biologics and Oxford BioTherapeutics Ltd. announced that OBT has selected a second bispecific program that will combine an anti-PD-L1 antibody with OBT’s immuno-oncology (IO) candidate, OX003. OBT will research and develop OX003/PD-L1, which employs WuXi Biologics’ proprietary bispecific antibody platform WuXiBody®.

Latest news about WuXi Biologics (Cayman) Inc.

Bank of China Downgrades Wuxi Biologics (Cayman) to Hold From Buy, Price Target is HK$14	Jun. 27	MT
Wuxi Biologics Terms US Plant's Expansion Halt as Normal Business Adjustment	Jun. 19	MT
WuXi Biologics Surges to 19-Month High Wednesday on Hopes of Avoiding US Ban	Jun. 13	MT
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	Jun. 01	RE
US lawmakers ask FBI for briefing on GenScript Biotech's links to China	May. 31	RE
China stocks rise as industrial profits grow; energy, semiconductor shares lead gains	May. 27	RE
Wuxi Biologics (Cayman) Maintains it is Not a Security Threat After House Bill Changes; Stocks Drop 3%	May. 17	MT
US House committee advances bill to restrict BGI, WuXi AppTec	May. 15	RE
US House committee to vote on bill to restrict BGI, WuXi AppTec	May. 15	RE
US Congress Drafts Bill Asking Drug Firms to Unlink from Chinese Biotech Firms	May. 14	MT
WuXi Shares Volatile as U.S. Bill Revised to Set Deadline for Decoupling	May. 13	DJ
U.S. bill to restrict WuXi AppTec, other Chinese biotech cos revised to give more time to cut ties	May. 10	RE
Pacific Assets Trust cautiously optimistic after outpacing benchmark	Apr. 30	AN
Wuxi Biologics Inc. Announces Retirement of Weichang Zhou as Chief Technology Officer and President of Global Biologics Development and Operations and Re-Designates as Non-Executive Director and Honorary President of Global Biologics Development and Operations and Senior Advisor to Chief Executive Officer	Apr. 01	CI
WuXi Biologics' 2023 Profit Falls 23% Despite Revenue Jump	Mar. 27	MT
WuXi Biologics 2023 Net Profit Fell on Higher Expenses, Impairment Losses	Mar. 26	DJ
WuXi Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Hong Kong Shares Slip Amid Downbeat Earnings, Cautious Trade	Mar. 19	MT
WuXi AppTec's Shares Fall After Downbeat Guidance	Mar. 19	DJ
WuXi AppTec's Net Profit Jumps, Reiterates It Doesn't Pose Security Threat	Mar. 18	DJ
WuXi Biologics Inc.(SEHK:2269) dropped from S&P International 700	Mar. 17	CI
WuXi Biologics Inc.(SEHK:2269) dropped from S&P Global 1200	Mar. 17	CI
Hong Kong Shares Drop as PBoC Keeps Key Policy Rate Unchanged	Mar. 15	MT
WuXi Shares Fall as Washington Lobbying Group Cuts Ties	Mar. 14	DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	Mar. 14	RE

Chart WuXi Biologics (Cayman) Inc.

Duration

Period

More charts

Company Profile

WuXi Biologics (Cayman) Inc is an investment holding company principally engaged in the provision of end-to-end solutions and services for biologics discovery, development and manufacturing to customers involving in biologics industry. The Company mainly operates its business through two segments. The Biologics segment mainly engages in the provision of biologics discovery, development and manufacturing. The WuXi XDC (XDC) segment mainly engages in the provision of contract research, development and manufacturing organization (CRDMO) services for antibody-drug conjugate (ADCs) and various bioconjugates. The Company mainly conducts its business in the domestic and overseas markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-18 - Q2 2024 Earnings Release (Projected)

Related indices

HONG KONG HANG SENG

More about the company

Income Statement Evolution

More financial data

Ratings for WuXi Biologics (Cayman) Inc.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.49 CNY

Average target price

20.93 CNY

Spread / Average Target

+99.52%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
WUXI BIOLOGICS (CAYMAN) INC.	-61.96%	6B
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+23.26%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-15.13%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs